Study reveals vaccine response in immunocompromised individuals
NCT ID NCT04780659
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study looked at how the COVID-19 mRNA vaccine (Comirnaty) works in people with weakened immune systems, such as those with HIV, organ transplants, or certain blood cancers, compared to healthy individuals. About 539 adults received two vaccine doses, and researchers measured their antibody levels and side effects. The goal was to understand if the vaccine triggers a strong immune response in these vulnerable groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Karolinska University Hospital
Stockholm, Huddinge, 14186, Sweden
Conditions
Explore the condition pages connected to this study.